The European Commission recently approved the oral version of Wegovy (semaglutide 25 mg) for adults with obesity and at least one weight-related comorbidity, according to Novo Nordisk. This regulatory milestone makes Wegovy the first GLP-1 tablet authorized for weight management in the European Union, following previous approvals in the United States, United Kingdom, United Arab … Read more
Eli Lilly and Company is acquiring biotech firm AtaiBeckley for an up-front payment of $2.8 billion to integrate the psychedelic drug candidate BPL-003 into its neuroscience portfolio. According to company terms, Lilly will pay $6.75 per outstanding share, with potential milestone payments reaching an additional $1 billion ($2.50 per share), according to the deal terms. … Read more
An unidentified 79-year-old patient gained access to the experimental obesity drug retatrutide through the FDA’s compassionate use pathway, according to reports from STAT News and The New Republic. While speculation persists regarding the patient’s identity, federal agencies have declined to confirm if the individual is former President Donald Trump. The drug was requested in April … Read more
New York University professor Scott Galloway suggests investors pivot from volatile high-profile IPOs toward the pharmaceutical sector, specifically targeting companies producing GLP-1 receptor agonists. Following SpaceX’s June 12 IPO, which saw shares fluctuate, Galloway argued in a June 17 Medium post that market demand for the space company is artificially inflated. Instead, he highlights GLP-1 … Read more
Health authorities in Victoria have issued an urgent alert after six people were hospitalized with acute liver toxicity linked to the use of an unapproved, black-market injectable peptide marketed as “retatrutide.” Medical experts, including specialists at the Victorian Liver Transplant Unit, warn that products sold online or through informal channels are unregulated, counterfeit, and pose … Read more
The Intersection of AI and Biotech: A New Investment Paradigm The healthcare landscape is undergoing a tectonic shift. As venture capital flows increasingly toward artificial intelligence, the traditional boundaries of health-tech are blurring. We are moving beyond simple digital records into an era where predictive modeling and automated diagnostics are not just luxuries, but operational … Read more
The Weight-Loss Revolution: How Biotech is Rewriting Global Health Driving through the quiet, rolling farmland of Dunderrow, Ireland, you would never guess you are approaching the epicenter of a global medical revolution. Yet, hidden within Eli Lilly’s sprawling 50-hectare campus, the future of human health is being manufactured at an unprecedented scale. View this post … Read more
The Trillion-Dollar Shift: Navigating the Future of Healthcare Investing The economic landscape of healthcare is undergoing a seismic shift. According to the Committee for a Responsible Federal Budget, federal healthcare spending is projected to climb from less than $2 trillion today to more than $3 trillion within a decade. View this post on Instagram about … Read more
AI-Powered Drug Discovery: Lilly and Insilico Medicine Forge a $2.75 Billion Partnership The pharmaceutical landscape is undergoing a seismic shift, driven by the integration of artificial intelligence (AI) into drug discovery. A recent collaboration between Eli Lilly and Insilico Medicine, valued at up to $2.75 billion, exemplifies this trend. The deal, announced on March 29, … Read more
Ozempic’s Patent Cliff: A Global Shift in Diabetes and Weight Loss Treatment A pivotal moment is unfolding in the pharmaceutical landscape as patent protections for semaglutide – the active ingredient in both Ozempic (for diabetes) and Wegovy (for weight loss) – expire in key global markets. This expiration, beginning Saturday, March 28, 2026, is poised … Read more